Profound Medical reported that whole-gland TULSA preserved penile length at 1 month versus a 0.65 cm median reduction after robotic radical prostatectomy.Key Highlights:Original SEC Filing: Profound Medical Corp. [ PROF ] - 8-K - Jul. 24, 2026This is an AI-powered summary. It may contain inaccuraci…
– Whole-gland TULSA ablation demonstrates statistically significant superior penile length preservation compared to robotic RP at 1 month –TORONTO, July 24, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device compan…
Profound Medical will release second quarter 2026 financial results after market close on August 6, 2026 and host a 4:30 p.m. ET conference call to discuss them.Key Highlights:Original SEC Filing: Profound Medical Corp. [ PROF ] - 8-K - Jul. 16, 2026This is an AI-powered summary. It may contain ina…
TORONTO, July 15, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. NASDAQ:PROF; TSX:PRN (“Profound” or the “Company”) is pleased to announce that its MRI-guided, AI-powered, Robotically-Driven and Incisionless TULSA Procedure™ will be highlighted in several presentations by leading physicians at the…
